Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.57 | N/A | +5.85% |
management commentary, guidance changes, and full analysis available with Pro.
| +5.85% |
Tone: Cautiously Optimistic
Overall, management expressed confidence in their future growth potential despite not providing specific guidance. They noted the importance of innovation in driving results.
Management highlighted the strength of their product pipeline.
They emphasized ongoing investments in research and development.
Amgen's earnings report shows a positive surprise in EPS, indicating better-than-expected profitability. The stock reacted modestly, rising by 0.13%, likely driven by the strong EPS performance and management's positive outlook on their product pipeline. However, the lack of revenue figures and guidance may leave investors cautious.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NORFOLK SOUTHN CORP
Jul 27, 2015